Torrent Pharmaceuticals Ltd recently spelt out plans to target the first wave of semaglutide launches, with patents on the glucagon-like peptide (GLP-1) receptor agonist set to expire in March 2026 in India and Brazil, both being markets in which it has a strong presence.
Torrent Says GLP-1 Market Size Uncertain; Pricing Edge For Oral Drugs
Supply Not A Major Concern
As Torrent joins Indian majors with plans to launch semaglutide in India and Brazil post patent expiry, market access topics like price and demand come up for discussion. Meanwhile, the supply chain is seen overcoming shortages
More from India
More from Therapy Areas
• By
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.
• By
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.